Exelixis (EXEL) Other Working Capital Changes (2017 - 2023)
Exelixis (EXEL) posted quarterly Other Working Capital Changes of $162000.0 for Q2 2023, up 124.47% year-over-year from $72169.6 in Q2 2022, and up 122.91% quarter-over-quarter from -$707000.0 in Q1 2023.
Analysis
Exelixis (EXEL) Other Working Capital Changes (2017 - 2023) Analysis & Trends
Exelixis' Other Working Capital Changes history runs 7 years deep, the most recent figure standing at $162000.0 for Q2 2023.
- In Q2 2023, Other Working Capital Changes rose 124.47% year-over-year to $162000.0; the TTM figure through Jun 2023 stood at -$1.2 million (down 608.28% YoY), while the FY2023 annual figure was -$3.1 million, down 26.46% from the prior year.
- Other Working Capital Changes for Q2 2023 stood at $162000.0, up from -$707000.0 in the prior quarter.
- The five-year high for Other Working Capital Changes was $104.7 million in Q3 2025, with the low at -$94.1 million in Q1 2025.
- The 5-year median for Other Working Capital Changes is $1.8 million (2023), against an average of $6.0 million.
- The sharpest annual moves came in 2020 and 2022: Other Working Capital Changes jumped 774.03% in 2020, then sank 162.21% in 2022.
- Exelixis' Other Working Capital Changes stood at -$1.1 million in 2019, then surged by 931.77% to $8.8 million in 2020, then tumbled by 104.81% to -$426000.0 in 2021, then surged by 251.88% to $647000.0 in 2022, then sank by 74.96% to $162000.0 in 2023.
- Business Quant data shows EXEL's Other Working Capital Changes at $162000.0 in Q2 2023, -$707000.0 in Q1 2023, and $647000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 162,000.00 |
| Jun 30, 2023 | 162,000.00 |
| Mar 31, 2023 | -707,000.00 |
| Mar 31, 2023 | -707,000.00 |
| Dec 30, 2022 | 647,000.00 |
| Dec 30, 2022 | 647,000.00 |
| Sep 30, 2022 | -1.30 Mn |
| Sep 30, 2022 | -1.30 Mn |
| Jul 1, 2022 | -662,000.00 |
| Jul 1, 2022 | -662,000.00 |
| Apr 1, 2022 | -1.17 Mn |
| Apr 1, 2022 | -1.17 Mn |
| Dec 31, 2021 | -426,000.00 |
| Dec 31, 2021 | -426,000.00 |
| Oct 1, 2021 | 2.09 Mn |
| Oct 1, 2021 | 2.09 Mn |
| Jul 2, 2021 | -4.08 Mn |
| Jul 2, 2021 | -4.08 Mn |
| Apr 2, 2021 | 13.42 Mn |
| Apr 2, 2021 | 13.42 Mn |